

IN THE CLAIMS

Please amend the claims as shown in the marked-up copy following this amendment to read as follows.

3. (Amended) The use as claimed in claim 1, characterized in that said composition comprises between 0.1 and 5 $\mu\text{g/ml}$, preferably between 0.5 and 2.5 $\mu\text{g/ml}$, of soluble form of HLA-G.

REMARKS


Claims 1- 7 are active in the present application. Claim 3 has been amended for clarity and to remove multiple dependencies. No new matter is added by the amendment to Claim 3.

In addition, the specification has been amended to insert a substitute Sequence Listing, and a Computer Readable Sequence Listing (CRF) is attached herewith. The contents of the paper copy of the substitute Sequence Listing and the contents of the (CRF) submitted herewith are identical. Support for all the sequences listed in the substitute Sequence Listing can be found in the present application as originally filed. No new matter is introduced by the submission of the substitute Sequence Listing.

Applicants submit that the present application is now in condition for examination on the merits. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

James J. Kelly, Ph.D.
Registration No.: 41,504



22850

(703) 413-3000
Fax #: (703) 413-2220
NFO/JK/TWB:twb:aps
I:\atty\Twb\2002\6-02\217365us-pr2.wpd

217365US-0PCT

Marked-Up Copy

Serial No: 09/926,778

Amendment Filed on:
HEREWITHIN THE SPECIFICATION

After page 24 (Abstract), beginning on a new page, please delete the original Sequence Listing at page 1 and insert the substitute Sequence Listing attached hereto.

IN THE CLAIMS

Please amend the claims as follows.

--3. (Amended) The use as claimed in claim 1 [or claim 2], characterized in that said composition comprises between 0.1 and 5 µg/ml, preferably between 0.5 and 2.5 µg/ml, of soluble form of HLA-G.--